Radioimmunoassay of neocarzinostatin, an antitumor protein.
Antibodies directed toward the antitumor protein neocarzinostatin (NCS) have been produced in a rabbit by immunization with a highly purified NCS preparation. The antiserum was monospecific and reversed the antibacterial activity of NCS against Sarcina lutea. It cross-reacted with chemically modified derivatives of NCS and mitomalcin but failed to cross-react with macromomycin. A radioimmunoassay procedure has been developed utilizing the antiserum and a biologically active 125I-labeled derivative of NCS. The lower limit of detection by this radioimmunoassay, which involves a double antibody technique for the separation of antibody-bound and free antigen, was 1 X 10(-13) mole. The sensitivity of the assay is such that serum levels of NCS can be determined accurately after administration of the drug to rats at a single dose of 2 mg/kg. Since NCS is now undergoing clinical trial, the radioimmunoassay of the drug will be a valuable tool in clinical pharmacological studies.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000032:analysis*; D000906:Antibodies; D000937:Antigen-Antibody Reactions; D003429:Cross Reactions; D000939:Epitopes; D005779:Immunodiffusion; D007457:Iodine Radioisotopes; D011233:Precipitin Tests; D011863:Radioimmunoassay; D051381:Rats; D012505:Sarcina / Q000187:drug effects; D009353:Zinostatin / Q000031:analogs & derivatives / Q000032:analysis* / Q000276:immunology
D000903:Antibiotics, Antineoplastic; D000906:Antibodies; D000939:Epitopes; D007457:Iodine Radioisotopes; D009353:Zinostatin